Loading...
NPI 1881906121 · Reno, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Juan Cattoni is a hematology & oncology physician provider located in Reno, Nevada. This profile covers 63 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Juan Cattoni |
| Address | 5423 Reno Corporate Dr. |
| City | Reno |
| State | NV |
| ZIP | 89511 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | July 1, 2010 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.2M |
| Medicaid | $240 |
This provider is a hematology/oncology physician in Reno, NV with a long Medicare enrollment: NPI enumerated 2010-07-01 (about 16 years ago), consistent with an established practice likely focused on oncology care and ongoing outpatient management. The CPT/HCPCS mix is centered on high-cost oncology drug administration and E/M visits, indicating a clinic-based infusion practice rather than primarily inpatient-only work.
Medicare revenue dominates this profile: total Medicare revenue is $1.2M versus total Medicaid revenue of $240, so the provider is effectively single-payer at scale with Medicare driving virtually all reported payer dollars. Medicaid billing is negligible relative to Medicare and consists entirely of a low-reimbursement lab code (85025) for $231, indicating minimal engagement with the Medicaid population.
Revenue concentration on Medicare is heavily focused in a few biologic oncology drugs: the precomputed top 3 Medicare codes account for 79.5% of total Medicare revenue. The largest single Medicare code is J9271 (pembrolizumab) generating $533.2K (43.9% of Medicare revenue), followed by J9144 (daratumumab) at $317.5K (26.1%), and the office visit code 99214 at $115.3K (9.5%). This mix points to a practice that derives most of its Medicare income from high-volume monoclonal antibody infusions with routine E/M visits supporting ongoing therapy.
Operationally, the high volumes for specific injectable oncology agents (J9271 and J9144) and supportive-care codes (96413, Q5111) suggest the provider runs regular infusion sessions and manages complex cancer therapies and associated supportive care. The presence of chemotherapy administration add-on and infusion codes (96413, 96417, 96415, 96365) alongside high use of drug J0185 and device/flush code 96523 supports an active infusion workflow with ancillary services billed in-clinic.
Competitive standing versus national peers is mixed: J9271 ranks #910 of 1841 providers (50th percentile) and J9144 ranks #276 of 615 providers (54th percentile), indicating roughly typical national volumes for these high-revenue drugs rather than market dominance. By contrast, the E/M code 99214 is an extreme outlier nationally (ranks #7325 of 479517, 98th percentile), meaning the provider bills far more for moderate-complexity established outpatient visits than most peers, which may reflect a high outpatient visit cadence tied to therapy management.
Medicaid activity is concentrated entirely in a single lab code: 85025 accounts for 100.0% of the provider’s Medicaid revenue ($231) and ranks #140 of 157 in-state (10th percentile). This confirms minimal Medicaid engagement and no substantive Medicaid infusion or oncology drug billing. From a payer strategy perspective, the provider’s business is Medicare-centric and not meaningfully exposed to Medicaid populations.
Several codes show statistically notable deviations from peers in different directions: 99214 is labeled an "extreme outlier" (very high relative volume), while 99215 and 96523 are described as "notably above typical" (96th and 95th percentiles respectively), indicating higher-than-typical billing for higher-complexity visits and venous access maintenance. Most chemotherapy and drug administration codes, however, are described as "typical, unremarkable volume," suggesting the clinic’s drug use patterns are consistent with expected oncology practice volumes rather than concentrated specialist dominance.
Taken together, the billing profile indicates a stable, clinic-based hematology/oncology practice dependent on Medicare reimbursements for expensive biologic infusions and frequent outpatient management visits. The combination of high-revenue immunotherapy/monoclonal antibody codes plus an outsized E/M billing footprint highlights a service line focused on ongoing infusion therapy management for Medicare beneficiaries rather than broad-based Medicaid or inpatient-focused oncology services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
63 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 12,400 | $40 | $533.2K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 8,820 | $40 | $317.5K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,190 | $100 | $115.3K |
| J0897 | Injection, denosumab, 1 mg | 2,700 | $20 | $48.6K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 320 | $140 | $43.9K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 370 | $100 | $37.7K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 260 | $100 | $25.9K |
| J9041 | Injection, bortezomib, 0.1 mg | 1,820 | $10 | $9.1K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 1,060 | $10 | $8.5K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 1,000 | $10 | $8K |
Showing 1–10 of 63
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 63 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
63 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 21 | 40 | 13,000 | $40 | $625.8K |
| J9144 | 9 | 10 | 9,180 | $40 | $445.4K |
| J0897 | 42 | 70 | 3,630 | $20 | $94.6K |
| Q5111 | 8 | 10 | 400 | $110 | $46.4K |
| J9217 | 33 | 40 | 120 | $130 | $23.9K |
| 96413 | 15 | 70 | 210 | $100 | $23.7K |
| 99232 | 885 | 1,340 | 140 | $60 | $23.7K |
| 84443 | 63 | 80 | 50 | $20 | $22.7K |
| 80053 | 40 | 100 | 160 | $10 | $22.2K |
| 99214 | 70 | 3,610 | 110 | $80 | $19K |
Showing 1–10 of 63
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 30 | $10 | $230 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 140 | 160 | 1,190 | $1 | $39.8K |
Other providers in the same ZIP code as Juan Cattoni, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.